



Research Article

Role of intrathecal nalbuphine on prevention of postspinal shivering after knee arthroscopy



Ashraf M. Eskandr^{a,*}, Ayman M. Ebeid^b

^a Department of Anesthesia and Surgical Intensive Care, Faculty of Medicine, Menoufiya University, Shebeen Elkoom, Egypt

^b Department of Orthopedic Surgery, Faculty of Medicine, Menoufiya University, Shebeen Elkoom, Egypt

Received 10 May 2015; accepted 2 January 2016

Available online 2 March 2016

KEYWORDS

Spinal anesthesia;
Shivering;
Nalbuphine;
Thermoregulation

Abstract *Background:* Shivering associated with spinal anesthesia is a common and uncomfortable problem and may interfere with monitoring, oxygen consumption and carbon dioxide production. The aim of the study was to evaluate the effect of intrathecal nalbuphine on the prevention of shivering during spinal anesthesia in patients undergoing knee arthroscopy.

Methods: 60 patients (ASA physical status I or II) scheduled for knee arthroscopy under spinal anesthesia were randomly assigned to one of two equal groups: Group C (control group, $n = 30$) receiving 2.5 ml of 0.5% bupivacaine during spinal anesthesia; and Group N patients (nalbuphine group, $n = 30$) receiving 2.5 ml of a mixture of 400 μg nalbuphine plus 0.5% bupivacaine during spinal anesthesia. Before commencing regional anesthesia, standard monitoring was established and patients were given intravenous 15 ml/kg/h of crystalloid solution (at room temperature 23–25 °C). All operations were performed in the same operating room which maintained at a constant temperature of 23–25 °C and no means of active warming were used. Mean arterial blood pressure (MAP), heart rate (HR), arterial oxygen saturation (SPO₂), core (tympanic) temperature, the incidence and severity of shivering were all determined and recorded at baseline and every 10 min after anesthesia till end of surgery.

Results: Shivering was observed in 19 patients (63.3%) in control group and 7 patients in nalbuphine group (23.3%) with significant difference between the two groups ($P = 0.004$) and significant difference in intensity of shivering and core temperature ($P < 0.001$). No significant statistical difference was observed as regards hemodynamic parameters and oxygen saturation between the two groups.

Conclusion: Intrathecal nalbuphine is an effective and safe method to prevent shivering during spinal anesthesia in patients undergoing knee arthroscopy.

© 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Shivering is a common post-operative event, defined as an involuntary, repetitive activity of one or more skeletal muscles. The incidence of shivering has been found to be high, approximately 40–50% in different studies [1]. Postanesthetic

* Corresponding author at: 3, Yassin Abd Elghafar st., Shibin Elkoom, Menoufiya, Egypt. Tel.: +20 1001960697.

E-mail address: ameskandr@yahoo.com (A.M. Eskandr).

Peer review under responsibility of Egyptian Society of Anesthesiologists.

shivering leads to feelings of discomfort in the patient as well as an increase in oxygen consumption, carbon dioxide production, catecholamine release, cardiac output, intraocular pressure and complications such as tachycardia and hypertension. In addition to this, shivering may inhibit accurate monitoring by causing artifacts in the monitor [2–5]. Shivering also increases intracranial pressure, and may contribute to increased wound pain, delayed wound healing, and delayed discharge from post-anesthetic care [6,7].

The treatment of shivering includes both pharmacological and non-pharmacological methods. The non-pharmacological management is by external heating like the use of forced air warming, warming blankets, and warmed fluids. According to the results of a meta-analysis, the most frequently reported pharmacological interventions include clonidine, pethidine, tramadol, nefopam and ketamine [8]. Unfortunately, no gold standard treatment is known for shivering as the administration of all the available drugs is associated with various adverse effects.

Nalbuphine is a lipophilic semi-synthetic opioid related to both oxymorphone and naloxone, and it has relatively potent μ -antagonist and κ -agonist activities. Because of its κ -antagonist properties, nalbuphine should produce fewer μ -mediated side effects such as respiratory depression, pruritus, nausea and vomiting [9]. It has a high affinity for κ -opioid receptors in the central nervous system. Theoretically, nalbuphine may have a significant effect on postanesthetic shivering [9]. Intrathecal nalbuphine was widely used for postoperative analgesia in many studies [9,10].

The present study designed to study the effect of intrathecal nalbuphine on prevention of postspinal shivering in patients undergoing knee arthroscopy.

2. Materials and methods

This study was performed between January 2013 and August 2013 after approval of ethical committee of Faculty of Medicine, Menoufiya University and Pan African Clinical Trial Registry (www.pactr.org) PACTR 201505001091143. In a prospective, controlled, randomized clinical trial, after receiving written consent from patients, 60 patients, 20–60 years of both sex and American Society of Anesthesia (ASA) physical status I or II scheduled for knee arthroscopy under spinal anesthesia were enrolled. Patients with contraindications to regional anesthesia, allergy to the study medication, and obese with body mass index (BMI) > 30 were excluded. Patients were randomly assigned to one of two groups through closed envelop technique. Group C (control group, $n = 30$). Group N (nalbuphine group, $n = 30$). Before commencing regional anesthesia, standard monitoring was established and patients were given intravenous 15 ml/kg/h of crystalloid solution (at room temperature 23–25 °C) through an 18-gauge peripheral venous catheter. Oxygen 5 L/min was administered through a mask during anesthesia and patients were covered with drapes but not actively warmed. Spinal anesthesia was performed in the setting position at the L3–4 or L4–L5 levels, midline approach by 25-gauge Quinkle needle using 2.5 ml hyperbaric bupivacaine, 5 mg/ml in group C and 2.5 ml of a mixture of 400 μ g nalbuphine plus hyperbaric bupivacaine, 5 mg/ml. After the procedure, patients were positioned supine. Sensory levels were determined by pinprick and the motor

blockade was evaluated using Bromage's criteria. All operations were performed in the same operating room which maintained at a constant temperature of 23–25 °C and no means of active warming were used. The mean arterial pressure (MAP), heart rate (HR), arterial oxygen saturation (Spo₂), and core (tympanic) temperature were measured and recorded preoperative then every 10 min till the end of surgery. The incidence and severity of shivering were recorded during the operation and in the recovery room. Shivering was graded with a scale described by Bedside Shivering Assessment Score (BSAS) as follows [11]:

1. None: no shivering noted on palpation of the masseter, neck, or chest wall.
2. Mild: shivering localized to the neck and/or thorax only.
3. Moderate: shivering involves gross movement of the upper extremities (in addition to neck and thorax).
4. Severe: shivering involves gross movements of the trunk and upper and lower extremities.

Also any complications were recorded for example hypotension was defined as a decrease in the (MBP) to less 20% than the baseline value, which was treated with increments 5–10 mg of intravenous ephedrine. Bradycardia was defined as a decrease in HR less than 50 b/min which was treated with 0.5 mg IV atropine.

2.1. Statistical analysis

A power analysis was performed using a power of 90% and an α value 0.05. From previous clinical studies, we assumed that the incidence of shivering would be 20% in the nalbuphine group after premedication and 60% in the placebo group after premedication with a standard deviation 40. The sample size was calculated to be 29 patients so we decided to include 30 patients in each group in the study. We used Power and Sample size statistics program (PS version 3.0.43) for power analysis.

The collected data were analyzed by Statistical Package for Social Science (SPSS) version 16. Parametric data were expressed as mean \pm SD. The comparison of the mean \pm SD of two groups was done using the paired and unpaired Student's *t* test. Nonparametric data were expressed as number and percentage of the total number of patients. Determining the extent of a single observed series of proportions, difference from a theoretical or expected distribution was done using the Chi square test. *P*-value < 0.05 was considered statistically significant.

3. Results

The demographic data including age, sex, weight, height and the duration of surgery (Table 1) were comparable between both groups. The mean arterial blood pressure decreased in both groups from the baseline measurements with insignificant difference between the two groups (Table 2). As well as the heart rate decreased from the baseline with insignificant difference between the studied groups (Table 3). The number of patients receiving vasoactive agents was comparable between the two groups (6 vs 5). Three of eight patients in group C received ephedrine, two received atropine and one received both atropine and ephedrine. Three of the five patients in group N received ephedrine and two received atropine.

Download English Version:

<https://daneshyari.com/en/article/2756128>

Download Persian Version:

<https://daneshyari.com/article/2756128>

[Daneshyari.com](https://daneshyari.com)